[Cost effectiveness analysis of alendronate versus placebo in the prevention of hip fractures].
Hawkins Carranza
F
F
López Alvarez
M B
MB
D019386:Alendronate / Q000191:economics* / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D006620:Hip Fractures / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D010919:Placebos; D017698:Postmenopause; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D010919:Placebos; D019386:Alendronate